InnovaRx Innova Health Strategies

G83.4

Cauda equina syndrome

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 10 never code together
G83.4code
Excludes1
G00-G99chapter
Excludes2
  • certain conditions originating in the perinatal period (P04-P96)P04-P96
  • certain infectious and parasitic diseases (A00-B99)A00-B99
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations, and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • injury, poisoning and certain other consequences of external causes (S00-T88)S00-T88
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 3
G83code
Notes
  • This category is to be used only when the listed conditions are reported without further specification, or are stated to be old or longstanding but of unspecified cause. The category is also for use in multiple coding to identify these conditions resulting from any cause.
Includes
  • paralysis (complete) (incomplete), except as in G80-G82G80-G82
G83.4code
Inclusion terms
  • Neurogenic bladder due to cauda equina syndrome
Index entries leading here 4
  • Neurogenic — see also condition
  • Compression
  • Lesion (s) (nontraumatic)
  • Syndrome — see also Disease
Alongside this code 7 same parent — G83
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

CMS22HCC72 CMS28HCC182 ESRD21HCC72 ESRD24HCC72 RX08HCC155

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
G83
Block
G80-G83
Siblings
7

Present FY2024–FY2027.